L3VLUP
ProSign in

IRWD · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

IRWDVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • IRWD
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterIRWDVRTX
Q3 20207 holders, $251m31 holders, $21.9bn
Q4 20207 holders, $302m30 holders, $18.4bn
Q1 20213 holders, $272m31 holders, $15.4bn
Q2 20216 holders, $331m30 holders, $12.7bn
Q3 20213 holders, $236m35 holders, $10.1bn
Q4 20214 holders, $251m28 holders, $12.4bn
Q1 20223 holders, $240m23 holders, $16.1bn
Q2 20223 holders, $236m25 holders, $18.1bn
Q3 20224 holders, $204m22 holders, $18.4bn
Q4 20228 holders, $287m28 holders, $18.4bn
Q1 20236 holders, $108m26 holders, $21.4bn
Q2 20238 holders, $161m27 holders, $24.7bn
Q3 20235 holders, $108m33 holders, $24.3bn
Q4 20237 holders, $147m32 holders, $28.6bn
Q1 20245 holders, $108m31 holders, $29.8bn
Q2 20244 holders, $83m29 holders, $33.4bn
Q3 20242 holders, $35m27 holders, $33.5bn
Q4 20243 holders, $41m26 holders, $28.5bn
Q1 20251 holders, $19k21 holders, $35.4bn
Q2 20251 holders, $9k21 holders, $32.3bn
Q3 20251 holders, $17k22 holders, $25.9bn
Q4 20253 holders, $49m26 holders, $31.8bn
Q1 20262 holders, $23m25 holders, $31.8bn
Q2 20262 holders, $58m26 holders, $34.6bn
IRWD

Ironwood Pharmaceuticals Inc

Holders
3
Reported value
$41m
Buyers
2
Sellers
0

Breadth +2 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
26
Reported value
$28.5bn
Buyers
14
Sellers
13

Breadth +1 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2024

Among the 27 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only IRWD (1)

Farallon Capital Management LLC

Only VRTX (24)

AllianceBernstein LP, AQR Capital Management LLC, ARK Investment Management LLC, Artisan Partners LP, Baillie Gifford & Co, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Capital Research Global Investors, Capital World Investors, D. E. Shaw & Co., ExodusPoint Capital Management LP, Fidelity (FMR LLC), Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, T. Rowe Price Associates Inc, Voloridge Investment Management LLC, Wellington Management Group LLP, Winton Group Ltd, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →